Company intelligence / Profile preview

Alaunos Therapeutics

Houston, Texas, United States of Americaalaunos.com ↗

Ownership: Public · TCRT
Employees: ~35
Development stage: Phase 1

Overview

The company has demonstrated first-in-human response for non-viral TCR-T therapy targeting high frequency TP53 and KRAS driver mutations across multiple solid tumor indications. Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-up as of May 2023[5].

Therapeutic areas: Oncology
Modalities: T-cell receptor (TCR) cell therapiesGene-edited T cell therapies
Industry: Biotech

Drug pipeline

19 assets

ad-rts-hil-12

18 more assets in the full pipeline.

Request access →

Partnerships

MD Anderson Cancer Center

Financials

Market cap: $3.8M
Total revenue: $0
Enterprise value: $3.7M

Beyond the preview

Go deeper on Alaunos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alaunos Therapeutics.

Explore the full profile